

ΕΞΑΤΟΜΙΚΕΥΣΗ ΤΗΣ ΑΝΤΙΥΠΕΡΤΑΣΙΚΗΣ ΘΕΡΑΠΕΙΑΣ

Επιλογή φαρμάκων στη στεφανιαία
νόσο και την
καρδιακή ανεπάρκεια

Γ. Βυσσούλης
Αναπλ. Καθηγητής Καρδιολογίας
Μονάδα Υπέρτασης
Α΄ Καρδιολογική Κλινική Πανεπιστημίου Αθηνών

Post-MI Hypertension

β -blockers

Identified 82 randomized trials examining the effects of post-MI β -blockade.

51 acute trials (< 6 weeks after onset of pain)

31 long-term trials (6 weeks – 48 months)

Freemantle, et al (BMJ 1999;318)

Which β -blocker ?

These drugs reached significance:

| | |
|--------------------|----------------------------|
| Timolol | 0.59 (95% CI, 0.46 - 0.77) |
| Propranolol | 0.71 (95% CI, 0.59 - 0.85) |
| Metoprolol | 0.80 (95% CI, 0.66 - 0.96) |

These are lipophilic β -blockers - Atenolol and Sotalol are hydrophilic

Post-MI Hypertension

ACE Inhibitors

Review of 15 randomized trials (n = 15,104)


ACEI started within 14 days of MI treated for ≥ 6 weeks

Domanski et al. (JACC)

Mortality 0.83 (95% CI, 0.71-0.97)

Cardiovascular Death 0.82 (95% CI, 0.69-0.97)

Sudden Cardiac Death 0.80 (95% CI, 0.70-0.92)




SAVE

Radionuclide
EF \leq 40%




AIRE

Clinical and/or
radiographic
signs of HF



TRACE

Echocardiographic
EF \leq 35%




odds ratio (95% CI)

Flather MD et al, *Lancet* 2000;355:1575-1581

OPTIMAAL


All-cause mortality



| | | | | | | | |
|---------------|------|------|------|------|------|------|------|
| Losartan (n) | 2744 | 2504 | 2432 | 2390 | 2344 | 2301 | 1285 |
| Captopril (n) | 2733 | 2534 | 2463 | 2423 | 2374 | 2329 | 1309 |


ELITE II

Primary endpoint : All-cause mortality




CHARM Alternative

Primary outcome CV death or CHF hospitalisation




CHARM Preserved

Primary outcome CV death or CHF hospitalisation



CHARM Added

Primary outcome CV death or CHF hospitalisation



Granger B, *Lancet*, Published online, September 1, 2003




McMurray JJV, *Lancet*, Published online, September 1, 2003

Yusuf S, *Lancet*, Published online, September 1, 2003


β -Blockers in Heart Failure

All-Cause Mortality


US Carvedilol Programme



Nifedipine GITS improves key CV outcomes



RALES All-cause mortality



Algorithm for heart failure

Neurohormonal inhibiting drug therapy

Initiate diuretic and/or digoxin as indicated

Optimal therapy

Alternative therapy

Initiate ACEI

Initiate AIIIRA

Spironolactone →

← Spironolactone

Add β -blocker

↓
Monitor